Inside Drug Pricing - 06/29/2020

Gilead Prices Remdesivir At $390 Per Vial, $520 For Private Insurance

By Ariel Cohen / June 29, 2020 at 10:26 AM
The Trump administration has secured 500,000 treatment courses of Gilead’s experimental COVID-19 drug remdesivir, and hospitals will pay no more than $3,200 per average treatment course, HHS and Gilead announced Monday morning (June 29). This comes to $390 per vial for government-run health systems in the United States and other developed countries, and though Gilead will charge U.S private insurers more, up to $520 per vial, the overall cost is much less than some analysts anticipated. Remdesivir is the only...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.